Rotation or Change of Biotherapy After TNF blocker treatment failure for axial Spondyloarthritis: The ROC-SpA study
Phase of Trial: Phase IV
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs Secukinumab (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infliximab
- Indications Spondylarthritis
- Focus Therapeutic Use
- Acronyms ROC-SPA
- 05 Apr 2019 Status changed from not yet recruiting to recruiting.
- 26 Nov 2018 Planned initiation date changed from 15 Nov 2018 to 1 Dec 2018.
- 06 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 15 Nov 2018.